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A basic purpose of the Utah State University Quadrangle (formally the USU 
Faculty Association and Faculty Women's League) is to encourage the 
intellectual growth and development of its members by sponsoring and 
arranging for the publication of two annual faculty lectures in the fields of (1) 
the biological and exact sciences, including engineering, called the Annual 
Faculty Honor Lecture in the Natural Sciences; and (2) the humanities and 
social sciences, including education and business, called the Annual Faculty 
Honor Lecture in Humanities. 
This seventy-sixth lecture, continues a tradition which began in 1942. Over 
the years this series has served to honor USU's most outstanding scholars 
from every college in the University. 
Lecturers are chosen by a committee of the USU Quadrangle. Among the 
factors considered by the committee in choosing the lecturers are (1) creative 
activity in the field of the proposed lecture; (2) publication of research 
through recognized channels in the field of the proposed lecture; (3) 
outstanding teaching over an extended period of years; (4) personal influence 
in developing the character of students. 
Dr. Robert W. Sidwell was selected by the committee to deliver the seventy-
sixth Annual Faculty Honor Lecture in the Natural Sciences. 
AIDS: Implications to Society and 
Approaches to Control 
Introduction 
By 
Robert W. Sidwell 
Utah State University 
Logan, Utah 
It is perhaps a measure of today's society that a new disease of potentially 
world-wide implication does not gain national or international attention 
until a famous person contracts it. This was particularly seen with Acquired 
Immunodeficiency Syndrome (AIDS) when it became known that Rock 
Hudson of movie and TV acclaim was dying of it. By the time the celebrated 
pianist and entertainer Liberacedied of AIDS, the various public health 
agencies around the world had begun to focus on the problem, and enormous 
sums of money were being committed toward its control. Today, more U.s. 
dollars are budgeted for AIDS than are being spent for any other disease, 
including cancer (Figure 1). 
Figure 1. Federal Funding for AIDS (Combined Public Health Service, Federal Medicaid 
Share, Veterans Administration and Department of Defense) 
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AIDS has caused major changes in the scientific and social perspectives of 
the people of the United States and, perhaps to a lesser degree, to public 
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perspectives throughout the world. This is a deadly disease caused by a new 
pathogen of a class which previously has never been conclusively shown to 
be a public health problem. We have had to adjust our scientific sights to 
focus on this new disease agent-an adjustment which has resulted in 
astonishi.ng technological progress in learning of the etiology and means by 
which this new disease is spread. Such technological advancements, in 
addition to expanding our understanding of this new disease, may 
peripherally benefit the public in providing illumination on many other 
heretofore little known diseases. Unfortunately, science has thus far fallen 
short, however, of finding an acceptable cure for those with AIDS or of 
developing a vaccine for those who may be at risk. 
The disease is making a major economic impact, both on increasing the 
demand for more research dollars and in escalating costs for medical 
treatment which has led to significant changes in insurance coverages and 
fees. Since a major means of transmission of the AIDS pathogen is through 
sexual contact, significant changes in human sexual behavior have been 
mandated. 
It is the purpose of this lecture to provide a brief overview on AIDS: The 
disease, its etiology, some sociological effects and how our government is 
responding to the disease. I will end by reviewing some of the research being 
done at Utah State University (USU) toward control of this most significant 
new medical emergency. 
The Disease 
The disease of AIDS is not pretty, and people who die due to its effects 
usually do not do so quickly. The AIDS virus directly attacks several portions 
of the immune system. The primary target cell attacked is the helper T4 
lymphocyte, a white blood cell required by the body to initiate the necessary 
immune responses to protect the body. The loss of these T4 cells results in a 
systematic failure of a large part of the immune system. The virus also 
attacks the macrophage, another important white cell which functions in a 
variety of ways to provide immunologic protection. The destruction of these 
immune mechanisms leaves the body open to attack by what are known as 
opportunistic infections, which are caused by viruses, bacteria, fungi, and 
protozoa (Table 1) which are of little significance in the healthy individual. 
In addition, the patient is highly prone to develop certain cancers; Kaposi' s 
sarcoma, a cancer of the skin, and internal organs, is predominant. 
The resultant opportunistic diseases are devastating, usually leading to a 
slow, and painful death. 
The AIDS virus itself can cause clinical manifestations of disease. The 
macrophages infected by the virus migrate to many parts of the body and 
consequently are instrumental in the spread of the virus to cells of the brain, 
central nervous system, and spinal cord. The heart and blood-forming 
elements may also be attacked. Individuals infected in this manner often do 
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not display either the cancers or infectious diseases usually seen in AIDS 
patients. Instead, they exhibit dementia, severe emaciation, and occasional 
anemia, and are referred to as having AIDS-related complex (ARC). 
Table 1. Opportunistic Infections in AIDS Patients 
Organism 
Virus 
Cytomegalo" 
Herpes simplex 
Herpes zoster 
Epstein-Barr 
Bacteria 
Hemophilus influenza 
Mycobacterium avium-intracellulare" 
Mycobacterium kansasii 
Mycobacterium tuberculosis" 
Salmonella sp." 
Streptococcus pneumoniae 
Treponema pallidum 
Fungi 
Candida sp. 
Coccidiodes immitis" 
Cryptococcus neoformans" 
Histoplasma capsulatum" 
Protozoa 
Cryptosporidium 
Isospora belli 
Pneumocystis carinii" 
Toxoplasma" 
"Considered of major Significance 
Epidemiological Impacts 
Common Clinical Manifestations 
Retino-choroiditis, colitis, pneumonia 
Mucocutaneous (mouth, rectum) 
Dermatomal 
Hairy leukoplakia, possible neoplasia 
Pediatric upper respiratory, pneumonia, sepsis 
Disseminated infection 
Disseminated infection 
Pneumonia, disseminated infection 
Diarrhea, sepsis 
Pediatric upper respiratory, pneumonia, sepsis 
Neurosyphilis 
Esophagitis, stomatitis 
Disseminated infection 
Disseminated infection, meningitis 
Disseminated infection 
Enteritis 
Enteritis 
Pneumonia 
Encephalitis, retinochoroiditis 
J 
Probably the first case of AIDS in the United States involved a 15-year-old 
boy who died in 1969. The patient had small purplish lesions which were 
identified as Kaposi's sarcoma, and a major onset of chlamydia, a sexually 
transmitted viral disease. His immune system was functioning poorly at the 
time of his death. Samples of his body fluids and tissues were found 15 years 
later to be positive for the AIDS virus. l It is apparent that the virus present in 
this youth did not get widely spread, and no further cases of a similar nature 
were reported until 1981, when an immunodeficiency disease was seen in 
male homosexuals.2,3 Since that time, the number of cases in this country 
has rapidly increased, to a total of 137,385 through June 19904 (Figure 2). By 
this latter date, 84,164 deaths have been attributed to the disease in the U.s. 
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By 1992, our public health authorities predict over 365,000 cases-at least 1,000 
new cases for each day of the year.5 
Figure 2. Increase in Clinical AIDS Cases in the United States, 1981 through 1992 (predicted) 
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Some even more sobering statistics also confront us. The numbers just 
cited are clinical cases of AIDS. If we also consider those who are seropositive 
but do not yet have symptoms, the numbers jump to over one and one-half 
million cases in the United States right now.4 Thus the active cases are 
literally only the tip of the iceberg. By redefining of the scope of AIDS to 
include seropositive patients with those nearing death from AIDS as having 
"HIV disease," our medical authorities have then qualified the clinically 
healthy but seropositive patient for insurance benefits. This has subsequently 
raised the cost to care for such patients to an enormous extent.6 Estimates of 
the cost for the lifetime care for an AIDS patient have ranged from $61,800 to 
$94,000.6 Such marked increases in healthcare costs will ultimately affect us 
all in the pocket book. 
None of the above figures reflects the incidence of AIDS outside of the 
United States. The disease is considered to be found in essentially all the 
nations of the world. In Africa, the World Health Organization has estimated 
that at least 400,000 persons have AIDS, and about 3.5 million additional 
Africans may be seropositive? Most of these cases have been seen in central 
Africa, where literally entire towns have been decimated. We must 
recognize, too, that many countries in Africa are reluctant to admit the extent 
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of the disease in their area, so there is little doubt the incidence of AIDS is 
much higher than now reported. 
The AIDS nightmare in Africa and the response of some governmental 
officials there to it is illustrated in a recently described situation involving 
Tanzania.8 Researchers at Yale University's international health program 
planned to determine the prevalence of HIV disease in pregnant women in 
that country. They were to look for antibodies to the AIDS virus in maternal 
and infant cord blood. Unfortunately, Tanzanian officials would not allow 
the women to be told either why the blood was being taken or what were the 
results of the testing. They were concerned that hysteria might develop 
among the women because there was no cure for AIDS. In addition, 
Tanzania's medical care system was unable to provide adequate supportive 
services. Because U.s.-associated trials require "informed consent," the study 
had to be abandoned. 
The distribution of AIDS cases is interesting. Most of the infected patients 
are homosexual or bisexual men, followed by intravenous drug abusers 
(Figure 3). Hemophiliacs, transfusion recipients, and adults who participate 
in heterosexual activities are the primary other "at risk" groups. Note the 
information in the figure are 1986 statistics. Also shown, however, are the 
figures predicted for 1992, where it can be seen that a major shift occurs to 
sexually active women. We are already seeing this transmission of the AIDS 
virus from men to women occurring in much higher frequency.9 Not shown 
on the graph is the predicted major increase of AIDS in the perinatal 
population. The current U.s. statistics indicate a 38percent increase of the 
disease among infants in the past year.4 
The distribution of AIDS cases shifts dramatically in some other 
countries. In Africa, for example, women and children are now the hardest 
hit. Of the estimated 3.5 million seropositive persons in Africa, children 
under five constitute approximately 600,000.7 Infections are almost non-
existent in Africa among homosexuals. Thus, this is a disease which is not 
necessarily discriminating and is potentially capable of affecting many 
populations. One of the most touching photographs shown by an AIDS 
researcher at a recent medical conference was of an African hut with a girl 
about 12 years old standing in front of it holding a baby and with a toddler 
holding onto her leg. The researcher said that this was quite illustrative of 
the situation now occurring in Africa-both the parents had died of AIDS, 
and the baby eventually may as well. The entire burden of running the 
family had fallen to the 12-year-old. 
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Figure 3. Distribution of AIDS Cases in the United States, 1986 and 1992 (predicted) 
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The causal agent of AIDS has had several names: lymphadenopathy 
virus (LA V), human T lymphotrophic virus III (HTLV-III), AIDS-associated 
retrovirus (ARV), and, finally, human immunodeficiency virus (HIV). The 
latter name, HIV, is in common use at this time.1o It now appears that two 
types of HIV are responsible for AIDS. Type 1 (HIV-l) is the primary culprit, 
but recent evidences point to the emergence of type 2 HIV (HIV-2), which has 
similarities to simian immunodeficiency virus, an agent which causes an 
AIDS-like disease in nonhuman primates; HIV-2 has now been found in 
human populations in certain areas of Africa.II 
HIV is a member of the Retroviridae family of viruses, and is thus often 
referred to as a retrovirus. Until the onslaught of AIDS, no retrovirus had 
been conclusively shown to be a cause of human disease. Retroviruses have 
RNA for their genetic material, from which DNA is made which is 
incorporated into cells, changing the cells' genetic makeup so that Itew viral 
RN A can be synthesized and assembled into new virus particles. 
The viral DNA, once incorporated into the cell chromosome, may 
undergo a period of latency which can last years. Thus persons infected 
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initially with HIV may appear normal for long periods of time before the 
AIDS disease eventually develops. Despite the exposure to often very small 
amounts of virus through sexual contact, use of contaminated needles by 
drug abusers, or transfusions of contaminated blood products, an immune 
response to the virus is triggered. Antibodies to HIV subsequently appear in 
the blood and are used as ~m indicator of infection. Eventually, the latent 
infection is activated, and once this occurs, the virus will grow rapidly, and 
spread quickly to other cells throughout the body. The antibodies developed 
against the virus do not control the disease, which is in contrast to what 
happens in most virus diseases. The virus, in part, is transmitted cell-to-cell 
in a manner that it is not accessible to the antibody. Although HIV levels in 
the blood often decline with high antibody levels, considerable evidence is 
accumulating indicating that the anti-HIV antibodies may actually enhance 
the disease severity.12 The later destruction of the other immunological 
components in the body by the virus then leads to further increases in disease 
severity and to the opportunistic infections described earlier. 
The AIDS virus is an especially challenging entity. In addition to its 
effects on the immune system of the body, the virus also undergoes genetic 
variation, often in the same infected individual, during the period of 
infection.12 This mutation of segments of the HIV genome occurs at a much 
higher rate than is expected to occur in human genes. Such variations may 
pose complications particularly in the development of viral vaccines. 
A last point in this most simplified review of a highly complicated 
pathogen: HIV is relatively sensitive to destruction by normal conditions 
such as heat, light, and drying outside the body. Thus, transmission via 
casual contact such as on toilet seats, on lab benches, or breathing potentially 
contaminated air is unlikely and as yet has never been demonstrated. 
Although mosquitoes have been suspected of HIV transmission, considerable 
research has not shown this to occur. If it were not for the various exchanges 
of body fluids that occur in the human population, the spread of this virus 
would be no problem to us. 
The United States Government's Response 
The U.S. government's mechanisms for coping with the AIDS problem 
were both late in starting and slow to build up to render significant help. 
Today, however, as seen in Figure I, the total dollar appropriation into AIDS 
research has reached major proportions. An initial review of the figure 
might incur the response that too much is being spent on this disease; the 
difference between AIDS and diseases such as heart disease, cancer, and 
stroke, which now kill many more persons than AIDS, however, is the fact 
that the incidence of AIDS is increasing at an extremely rapid rate and 
expanding into new populations, whereas the other diseases, while at a high 
rate, are not increasing in such a dramatic fashion. 
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The federal approach has been multipronged, involving a major Public 
Health Service task force including the Centers for Disease Control, the 
National Institute of Allergy and Infectious Diseases (NIAID), the National 
Cancer Institute, the National Institute of Mental Health, the National 
Institute of Drug Addiction, the Food and Drug Administra tion, the 
Department of Defence, the Veteran Administration, and the Health 
Resources Services Administration. 
Within the NIAID, a new division has been formed, appropriately named 
the Division of AIDS. This Division has an Epidemiology Branch, a 
Biostatistics Research Branch, a Treatment Research Program, and a Basic 
Research and Development Program. These programs encourage and 
coordinate research involving much collaboration between medical workers 
and research scientists from the NIH itself, universities, nonprofit research 
institutes, pharmaceutical companies, and the rapidly multiplying 
biotechnology companies. With the innovative new Nationai Cooperative 
Drug Discovery Programs, it is not unusual for one grant application to have 
many subapplications, each from a different institution. 
A significant response by our government to the AIDS problem has been 
the literal "new age" of drug testing which aims to provide promising drugs 
to as many AIDS patients as possible. The drug testing concept, which has 
developed in part due to recommendations of AIDS activists, involves people 
with AIDS in the trial design, puts more emphasis on drugs for opportunistic 
infections, uses more flexible testing protocols and broader entry 
requirements, avoids the use of placebos, and involves the use of more 
sensitive disease parameters instead of death of the patient)3 In addition, 
considerable flexibility is being displayed by the U.s. Food and Drug 
Administration to get more new drugs into clinical trials faster. Such 
monumental changes in drug testing may go beyond the treatment of AIDS to 
apply to testing of drugs against other life-threatening diseases.13 
The AIDS research effort has begun to mature, and without question, no 
other virus has had so much learned about it so quickly .. More is known 
about HIV than is known about any other virus. Unfortunately, as has been 
reviewed, the virus is so complex, and the disease manifestations so 
extensive and challenging, that much more needs to be learned before the 
disease can be controlled or adequately treated. 
Treatment Difficulties 
Treatment of AIDS patients is being approached from several directions. 
Before reviewing the approaches to AIDS treatment, which is the thrust of 
our USU research, we should first consider the challenges involved in 
attempting such treatments. 
Since the AIDS virus becomes a part of the infected cell, often in a latent 
state for long time periods, the virus potentially may never be removed from 
the body by therapy, and treatments may need to be continued throughout the 
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lifetime of the infected individual. The occasional infection of brain tissues is 
a particular challenge to drugs, for they must cross the blood-brain barrier, 
which is high in lipid content and consequently almost impervious to any 
drugs not soluble in lipids. In addition, such therapies involving the brain 
should avoid having neurological effects, a complication difficult to avoid 
when drugs are found which can penetrate nervous tissue. 
Since the host's immune response has been compromised or perhaps 
essentially destroyed by the HIV infection, the body cannot assist the antiviral 
therapy, which often acts by inhibiting the viral growth but by itself does not 
eliminate the virus; the sagging immune response may need bolstering by an 
immune modulating drug which may thus be required to be used in 
combination with more standard antiviral therapies. 
The opportunistic infections which are usually the cause of death in the 
AIDS patient consist of a spectrum of disease agents, each requiring a different 
specific type of treatment. For some opportunistic pathogens, no therapies are 
yet known. Ideally, treatment may consist of therapy to stop the HIV 
combined with a drug or drugs to combat the opportunistic infection. Finally, 
the specter of drug-resistant viruses needs to be confronted. This is already 
beginning to be a problem.14 
Treatment Concepts 
Considering the above difficulties, treatment of AIDS can theoretically be 
approached by: 
1. Anti-HIV therapy using a substance designed to attack the virus or to 
inhibit its growth (Table 2). 
2. Anti-HIV therapy using cytokines, which are biological response 
modifiers produced by cells and which are becoming available in sufficient 
quantities to be of potential clinical use (Table 3). 
Table 2. Substances Now in Use or in Clinical Evaluatioll as Specific Anti-HIV Therapies15 
2',3' -Dideoxyadenosine (DDA) 
2',3'-Dideoxycytidine (DDC) 
2' ,3' -Dideoxyinosine (DDI) 
Acyclovir 
AL-721 
Amphotericin B 
Ansamycin 
Avarol 
AZidothymidine (AZT) 
Carrisyn· 
Cyanothymidine (CNT) 
D-Penicillamine 
Dextran sulfa te 
Foscarnet 
Fusidic acid 
GLQ223 (Compound Q) 
Glycyrrhizin sulfate 
HOE/BAY 946 
Hypericin 
Lentinan 
Peptide T 
Ribavirin 
• Also has immunomodulatory properties 
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Table 3. Cytokine Anti-HIV Therapies U"der Cli"ical Investigation15 
Anti-HIV antibodies 
Colony-stimulating factor 
Gamma globulin 
Interferon a, b, g 
Interleukin-I, 2, 3, 4 
Leukotoxin 
Thymosin-a 1 
Transfer factor 
Tumor necrosis factor 
3. Anti-HIV therapy using materials that block viral entry into cells. 
These include peptide T, which is part of the envelope glycoprotein of HIV; 
CD4, the protein receptor on certain cells to which HIV binds; and the 
polysaccharide, polymannoacetate. 
4. Stimulation of certain segments of the immune response using 
immunomodulators as a means of strengthening the system or to provide 
backup to any of the above HIV therapies (Table 4). 
Table 4. Immune Stimulators Under Clinical Investigation as Anti-AIDS Therapies15 
Ampligen 
AS-1OI 
Azimexon 
Carrisyn 
CL246,738 
Cyclosporin 
Imreg-I 
Imuthiol 
Isoprinosine 
LF1695 
Methionine-enkephaline (MET-ENK) 
M uramyl tripeptide 
Naltrexone 
Thymopentin 
5. Specific treatment of the opportunistic infection(s) occurring in the 
AIDS patient, including anticancer therapy for Kaposi's sarcoma. These are 
too extensive to discuss in this overview. 
6. Use of vitamins and appropriate diet to build up the patient. 
7. Selective destruction of HIV-infected cells resulting also in the 
elimination of the virus. This approach to date involves the use of 
immunotoxins, which are combinations of antibody against the cell to be 
killed conjugated with a toxic substance. The toxic substance is harmless 
unless it can be taken-into the cell-an event requiring the antibody to which 
it is attached. 
8. Perfusion of the AIDS patients' plasma through a prosorba column 
which removes circulating immune complexes which are involved in AIDS 
pathogenesis, blocking normal immune responses. 
9. Use of vaccines against all or part of the HIV genome. While not a 
treatment, it may be appropriate to include as the last approach in this review, 
although work with vaccines is literally the topic of a complete review in 
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itself. While early results with vaccines show some promise, much research 
remains to be done. 
Utah State University Studies 
The above review of the means to treat AIDS appropriately leads to a brief 
description of the AIDS research underway at USU. Our AIDS Research 
Group presently has two contracts with the National Institutes of Health; one 
is oriented toward developing therapies for a viral opportunistic infection 
associated with AIDS; in the other, research is being done into developing 
therapies for AIDS. 
Therapy for opportunistic infections: The project to develop an agent for 
treatment of opportunistic infections is a collaborative study with chemists at 
SRI International (Menlo Park, California). Potential new drugs synthesized 
at SRI are evaluated against experimentally induced cytomegalovirus 
infections and for potential toxicologic effects in our laboratories. Two 
potential new drugs which are chemically related to ganciclovir, the only 
clinically approved drug for treating human cytomegalovirus infections, 
have been developed through this joint research effort. These substances are 
the phosphonate monoethyl ester of ganciclovir and the phosphonate diacid 
of ganciclovir.16 Both new substances appear to be less toxic than ganciclovir, 
yet retain a strong antiviral potency (Table 5). Much is yet to be done in the 
development of these materials as drugs. 
Table 5. Treatment for Opportunistic Infections: Human Cytomegalovirus Inhibition of 
Phosphonate Analogs of Ganciclovir 
50% Cytotoxic 
Compound Dose (Jlg/ml) 
Ganciclovir 1000 
Phosphonate diacid 
of ganciclovir -2000 
Phosphonate mono-
ethylester of -2000 
ganciclovir 
"Cytotoxic dose + virus-inhibitory dose. 
50% Cytomegalovirus-
Inhibitory Dose (Jlg/ml) 
2 
2 
4 
Therapeutic 
Index" 
500 
1000 
500 
Studies with unique AIDS animal model: The research work to develop 
new therapies for AIDS underway at this university is involved particularly 
in the study of immunomodulators for the potential therapy of AIDS. Such 
research is challenging because we must use a small animal model which 
mimics, as much as possible, the AIDS disease in humans. The AIDS virus 
will not produce a disease in animals other than primates. A retrovirus of 
mice is thus employed, this being the Friend virus complex, which receives 
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its name from the scientist, Dr. Charlotte Friend, who originally discovered it. 
The Friend virus induces in mice a leukemia-like disease which will vary 
according to the genetic makeup of the animal. When special hybrid mice 
with the Rfv-3r / s, H-2a/ a and FV-3r / s genotype are infected, the resultant 
disease has many analogies to AIDS: in both infections, immunosuppression 
of the host occurs. Antibodies specific to the retrovirus occur in both the 
hybrid mouse and in man, yet both hosts are immunologically compromised 
if challenged by other disease agents. With the development of the antibody, 
only low levels of infectious virus can be found, yet the disease continues to 
progress. 
Our laboratory is unique in using this special mouse with defined genetic 
characteristics for use as an AIDS animal modeP7 We have found the 
clinically useful HIV-inhibiting drug zidovudine (AZT), to markedly inhibit 
the AIDS-like disease in this mouse model. Of considerable significance, 
however, is our recent finding18 that infected animals treated with AZT may 
appear to be "cured," i.e., free of all signs of the disease, including virus as 
sought by standard means. An apparently latent virus can still be seen, 
however, when extraordinary means are used for virus detection involving 
multiple co-cultivations of tissues from the animal with cultured cells of 
normal mice (Table 6). 
Table 6. Detection of Persisting Retrovirus in AZT-Treated Mice 
Treatment 
AZT, 80 mg/kg tid x 20 
Saline tid x 20 
"35 weeks after virus inoculation . 
Total Virus-positive 
Spleens Detected" by 
Standard Methodology 
0/31 
6/10 
.... Multiple co-cultivation with cultured indicator cells. 
Total Virus-positive 
Spleens Detected" After 
Viral Amplification .... 
14/31 
10/10 
Such results lend credence to the cry for new, better drugs for treatment of 
AIDS. As mentioned earlier, a possible approach for improving the efficacy of 
an antiviral drug such as AZT is to use a second drug in combination with 
the original antiviral drug. Ideally, the second drug should have a 
mechanism of action quite different from the initial drug. This is where the 
immunomodulators enter the scene, for the mechanisms by which these 
materials act are to enhance or modify the host immune system. Thus, a 
drug like AZT may specifically inhibit the replication of the virus in the cell, 
while the immunomodulating drug acts to bolster the fading immunity 
which results from the HIV infection. Such combinations are beginning to be 
studied in the clinic; it is one goal of the USU AIDS Research Program to help 
identify which combinations may be best for use in those clinical situations. 
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Our studies to date indicate 3 immunomodulators have potential for use in 
drug combinations. These materials are recombinant human interferon a, 
pyran copolymer (also known as MVE-2), and imexon, which has the 
chemical name 4-imino-1,3-diazobicyclo-(3.1.0)-hexan-2-one.19 
Use of genetically immunodeficient mice: A problem often encountered 
with potential irnrnunomodulating drugs is their failure to achieve in 
humans the significant immune modulation seen in lower animals such as 
mice. An approach being taken at USU is again to use a unique mouse 
model, in this case the Severe Combined Immunodeficient animal, usually 
referred to as the SCID mouse. These mice lack functional T or B cells, are 
hypogamma-globulinaemic, poor mitogen responders, and fail to reject 
allogenic skin grafts.20 In short, the animals are so lacking in a functional 
immune system that they are unable to reject foreign tissues introduced into 
their bodies. Thus, portions of a human immune system, such as found in 
human lymphocytes, can be injected into the SCID mouse, and, rather than 
being quickly eliminated by the animal, grow in the animal, literally 
reconstituting the mouse with the human immunity.21,22 We are using 
these human immunity-reconstituted SCID mice as a "next step" in the 
process of evaluating Biological Response Modifiers (BRM). It is most 
encouraging when a BRM will stimulate segments of the reconstituted 
human immune system in the SCID mouse in a similar manner to what is 
seen in regular mice. 
The immunological deficiencies of the SCID mouse have been shown by 
our group23 to allow the animals to become infected by Cryptosporidium, a 
serious parasitic infection afflicting AIDS patients. Until this infection was 
demonstrated in the SCID mouse, researchers have had difficulty finding an 
acceptable model which could be used to study this disease and the effects of 
possible therapies upon it. 
Transgenic animal research: A last challenge being targeted by our 
research program is how to deal with the latent virus or portion of the HIV 
genome which is being continually passed from one cell to its offspring. 
Again, a model is needed. In this case, we are collaborating with researchers 
at the Roche Institute of Molecular Biology (Nutley, New Jersey), and at the 
National Institutes of Health (Bethesda, Maryland) in the development of 
transgenic mice.24 Noninfectious segments of the HIV gene are inserted 
directly by micromanipulation into the fertilized mouse embryo, which in 
turn is transplanted into a healthy female mouse. The subsequent offspring 
are born with the HIV gene segment being expressed in certain of its tissues 
and are referred to as transgenic animals. The HIV gene segment is expressed 
in immune cells of the skin and can be activated to be expressed in 
lymphocytes and macrophages by factors known to activate the virus in HIV-
infected people. The offspring born later to these HIV gene-expressing mice 
similarly express the same gene, somewhat analogous to what occurs in man. 
We now have small colonies of these transgenic animals which are being 
used for the study of potential anti-AIDS drugs and BRMs. 
13 
Conclusions 
This brief overview has hopefully shown that AIDS is a most serious 
affliction which is spreading rapidly, and, as yet, is not readily controlled. The 
government's massive basic and clinical research response to this disease has 
yielded dramatic advances and will benefit us in control of other illnesses. 
Many approaches are being taken to the treatment of AIDS, and numerous 
therapies are under evaluation. The much sought-after cure of this deadly 
disease is probably still much into the future, however. 
The USU research programs I have described are a result of a truly 
collaborative effort involving scientists of many disciplines both from within 
the university as well as from highly regarded outside institutions (Table 7). 
Indeed, collaboration in research is the key for success in the battle against a 
most formidable and serious new plague, the disease of AIDS. 
Table 7. Senior Researchers Involved With the Utah State University AIDS Research 
Program 
Robert W. Sidwell 
John D. Morrey 
Reed P. Warren 
John H. Huffman 
Donald F. Smee 
Dale L. Barnard 
USU Researchers 
Thomas Bunch 
Mark C. Healey 
Kevin Jackson 
Michael Arrowood 
Jan Mead 
Kathleen Rasmussen 
Outside Collaborators 
Michael Hogan, Baylor College of Medicine 
Malcolm Martin, National Institutes of Health 
Elmer Reist, SRI International 
Craig Rosen, Roche Institute for Molecular Biology 
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